ProShares UltraShort NASDAQ Biotechnology
9 hedge funds and large institutions have $1.47M invested in ProShares UltraShort NASDAQ Biotechnology in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
29% more funds holding
Funds holding: 7 → 9 (+2)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
1.1% less ownership
Funds ownership: 8.05% → 6.95% (-1.1%)
26% less capital invested
Capital invested by funds: $1.99M → $1.47M (-$521K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$637K |
| 2 |
IMC Chicago
Chicago,
Illinois
|
+$316K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$128K |
| 4 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
+$62.3K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$17.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$928K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$254K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$154K |
| 4 |
WP
WealthSource Partners
San Luis Obispo,
California
|
-$27.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $553K | +$637K | +11,685 | +22,912% |
|
|
WP
2
WealthSource Partners
San Luis Obispo,
California
| $425K | -$27.3K | -500 | -5% |
|
|
3
IMC Chicago
Chicago,
Illinois
| $273K | +$316K | +5,802 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $110K | +$128K | +2,341 | New |
|
|
SFS
5
Sowell Financial Services
North Little Rock,
Arkansas
| $54K | +$62.3K | +1,143 | New |
|
|
6
Simplex Trading
Chicago,
Illinois
| $21K | -$154K | -2,822 | -86% |
|
7
Morgan Stanley
New York
| $19K | +$11.1K | +203 | +106% |
|
|
8
Osaic Holdings
Scottsdale,
Arizona
| $15K | +$17.1K | +313 | New |
|
9
Citigroup
New York
| $2K | – | – | – |
|
|
HF
10
HRT Financial
New York
| – | -$928K | -14,995 | Closed |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$254K | -4,104 | Closed |
|
BIS Hedge Fund Activity: Q4 2020 in Review
9 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2020, worth a combined $1.47M — down 26% from $1.99M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BIS positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $637K. The largest seller was HRT Financial, exiting entirely with an estimated $928K sold.
- 9 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2020, up from 7 in Q3 2020.
- Funds reported $1.47M of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2020, down 26% quarter-over-quarter.
- 4 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2020 and 2 closed out, a net change of +2 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2020 was Tower Research Capital (TRC), an estimated $637K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2020 was HRT Financial, an estimated $928K sold.
Based on aggregated 13F filings for Q4 2020.